nach oben

Erschienen in:

21.02.2020 | Others

Expert Consensus on clinical application of FDG PET/CT in infection and inflammation

verfasst von: Yaming Li, Qian Wang, Xuemei Wang, Xuena Li, Hua Wu, Quanshi Wang, Zhiming Yao, Weibing Miao, Xiaohua Zhu, Fengchun Hua, Xiaoli Zhang, Chao Cheng, Weifang Zhang, Qingyi Hou, Yuan Li, Xiao-Feng Li

Erschienen in: Annals of Nuclear Medicine | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

To further promote the clinical application of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in infection and inflammation and standardize the diagnostic process, the experts in relevant fields in China carried out discussion and formed the Expert Consensus on the clinical application of FDG PET/CT in infection and inflammation. This consensus is intended to provide a reference for imaging physicians to select a reasonable diagnostic plan. However, it should be noted that it couldn’t include or solve all the problems in clinical operation. Imaging physicians and technicians should develop a comprehensive and reasonable diagnostic procedure according to their professional knowledge, clinical experience and currently available medical resources when facing specific patients.

Goldman L, Schafer AI. Goldman-cecil medicine. 25thth ed ed. Amsterdam: Elsevier; 2016.

Vinay K, Abul KA, Jon CA. Robbins basic pathology. 10thth ed ed. Amsterdam: Elsevier; 2018.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeosxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–80.PubMed

Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation—current and emerging clinical applications. Clin Raiol. 2015;70(7):787–800.

Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI Guideline for ¹⁸F-FDG Use in Inflammation and Infection. J Nucl Med. 2013;54(4):647–57.PubMed

Besson FL, Chaumet-Riffaud P, Playe M, Noel N, Lambotte O, Goujard C, et al. Contribution of (18)F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43(10):1887–955.PubMed

Takeuchi M, Dahabreh IJ, Nihashi T, Iwata M, Varghese GM, Terasawa T. Nuclear Imaging for Classic Fever of Unknown Origin: Meta-Analysis. J Nucl Med. 2016;57(12):1913–9.PubMed

Schönau V, Vogel K, Englbrecht M, Wacker J, Schmidt D, Manger B, et al. The value of ¹⁸F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis. 2018;77(1):70–7.PubMed

Wang Q, Li YM, Li Y, Hua FC, Wang QS, Zhang XL, et al. ¹⁸F-FDG PET/CT in fever of unknown origin and inflammation of unknown origin: a Chinese multi-center study. Eur J Nucl Med Mol Imaging. 2019;46:159–65.PubMed

10.

Kim SJ, Lee SW, Jeong SY, Pak K, Kim K. A systematic review and meta-analysis of ¹⁸F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography for detection of infected prosthetic vascular grafts. J Vasc Surg. 2019;70(1):307–13.PubMed

11.

Rojoa D, Kontopodis N, Antoniou SA, Ioannou CV, Antoniou GA. ¹⁸F-FDG PET in the diagnosis of vascular prosthetic graft infection: A diagnostic test accuracy meta-analysis. Eur J Vasc Endovasc Surg. 2019;57(2):292–301.PubMed

12.

Sah BR, Husmann L, Mayer D, Scherrer A, Rancic Z, Puippe G, et al. Diagnostic performance of ¹⁸F-FDG-PET/CT in vascular graft infections. Eur J Vasc Endovasc Surg. 2015;49(4):455–64.PubMed

13.

Husmann L, Ledergerber B, Anagnostopoulos A, Stolzmann P, Sah BR, Burger IA, et al. The role of FDG PET/CT in therapy control of aortic graft infection. Eur J Nucl Med Mol Imaging. 2018;45(11):1987–97.PubMed

14.

San S, Ravis E, Tessonier L, Philip M, Cammilleri S, Lavagna F, et al. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in infective endocarditis. J Am Coll Cardiol. 2019;74(8):1031–40.PubMed

15.

Granados U, Fuster D, Pericas JM, Llopis JL, Ninot S, Quintana E, et al. Diagnostic Accuracy of ¹⁸F-FDG PET/CT in Infective endocarditis and implantable cardiac electronic device infection: A cross-sectional study. J Nucl Med. 2016;57(11):1726–32.PubMed

16.

Mahmood M, Kendi AT, Ajmal S, Farid S, O'Horo JC, Chareonthaitawee P, et al. Meta-analysis of ¹⁸F-FDG PET/CT in the diagnosis of infective endocarditis. J Nucl Cardiol. 2019;26(3):922–35.PubMed

17.

Li Y, Wang Q, Wang L. Localization and etiologic diagnosis of suspected pacemaker-related infection with ¹⁸F-FDG PET/CT. Chin J Nucl Med Mol Imaging. 2017;37(5):284–8 [Article in Chinese].

18.

Kiran M, Donnelly TD, Armstrong C, Kapoor B, Kumar G, Peter V. Diagnostic utility of fluorodeoxyglucose positron emission tomography in prosthetic joint infection based on MSIS criteria. Bone Joint J. 2019;101-B(8):910–4.PubMed

19.

Kumar R, Kumar R, Kumar V, Malhotra R. Potential clinical implication of (18) F-FDG PET/CT in diagnosis of periprosthetic infection and its comparison with (18) F-Fluoride PET/CT. J Med Imaging Radiat Oncol. 2016;60(3):315–22.PubMed

20.

Jin H, Yuan L, Li C, Kan Y, Hao R, Yang J. Diagnostic performance of FDG-PET or PET/CT in prosthetic infection after arthroplasty: a meta-analysis. Q J Nucl Med Mol Imaging. 2014;58:85–93.PubMed

21.

Basu S, Kwee TC, Saboury B, Garino JP, Nelson CL, Zhuang H, et al. FDG-PET for diagnosing infection in hip and knee prostheses: prospective study in 221 prostheses and subgroup comparison with combined 111In-labeled leukocyte/99mTc-sulfur colloid bone marrow imaging in 88 prostheses. Clin Nucl Med. 2014;39:609–15.PubMedPubMedCentral

22.

Lankinen P, Seppanen M, Mattila K, Kallajoki M, Knuuti J, Aro HT. Intensity of (18)F-FDG PET uptake in culture-negative and culture-positive cases of chronic osteomyelitis. Contrast Media Mol Imaging. 2017;2017:9754293.PubMedPubMedCentral

23.

van Vliet KE, de Jong VM, Termaat MF, Schepers T, van Eck-Smit BLF, Goslings JC, et al. FDG-PET/CT for differentiating between aseptic and septic delayed union in the lower extremity. Arch Orthop Trauma Surg. 2018;138(2):189–94.PubMed

24.

Demirev A, Weijers R, Geurts J, Mottaghy F, Walenkamp G, Brans B. Comparison of [18F] FDG PET/CT and MRI in the diagnosis of active osteomyelitis. Skeletal Radiol. 2014;43(5):665–72.PubMed

25.

Schmitz A, Risse JH, Grünwald F, Gassel F, Biersack HJ, Schmitt O. Fluorine-18 fluorodeoxyglucose positron emission tomography findings in spondylodiscitis: preliminary results. Eur Spine J. 2001;10:534–9.PubMedPubMedCentral

26.

Sminds C, Kouijzer IJ, Vos FJ, Sprong T, Hosman AJ, de Rooy JW, et al. A comparison of the diagnostic value of MRI and18F-FDG-PET/CT in suspected spondylodiscitis. Infection. 2017;45(1):41–9.

27.

Yin Y, Liu X, Yang X, Guo J, Wang Q, Chen L. Diagnostic value of FDG-PET versus magnetic resonance imaging for detecting spondylitis: a systematic review and meta-analysis. Spine J. 2018;18(12):2323–32.PubMed

28.

Kouijzer IJ, Blokhuis GJ, Draaisma JM, Oyen WJ, de Geus-Oei LF, Bleeker-Rovers CP. ¹⁸F-FDG PET/CT in detecting metastatic infection in children. Clin Nucl Med. 2016;41(4):278–81.PubMed

29.

Berrevoets MAH, Kouijzer IJE, Aarntzen EHJG, Janssen MJR, De Geus-Oei LF, Wertheim HFL, et al. ¹⁸F-FDG PET/CT optimizes treatment in Staphylococcus Aureus bacteremia and is associated with reduced mortality. J Nucl Med. 2017;58(9):1504–10.PubMed

30.

Vos FJ, Bleeker-Rovers CP, Sturm PD, Krabbe PF, van Dijk AP, Cuijpers ML, et al. ¹⁸F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med. 2010;51(8):1234–40.PubMed

31.

Brøndserud MB, Pedersen C, Rosenvinge FS, Høilund-Carlsen PF, Hess S. Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus. Eur J Nucl Med Mol Imaging. 2019;46(6):1351–8.PubMed

32.

Lantinga MA, Drenth JP, Gevers TJ. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant. 2015;30(5):744–51.PubMed

33.

Bobot M, Ghez C, Gondouin B, Sallée M, Fournier PE, Burtey S, et al. Diagnostic performance of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography in cyst infection in patients with autosomal dominant polycystic kidney disease. Clin Microbiol Infect. 2016;22(1):71–7.PubMed

34.

Jouret F, Lhommel R, Beguin C, Devuyst O, Pirson Y, Hassoun Z, et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:1644–50.PubMed

35.

Polizzotto MN, Millo C, Uldrick TS, Aleman K, Whatley M, Wyvill KM, et al. 18F-fluorodeoxyglucose positron emission tomography in kaposi sarcoma herpesvirus-associated multicentric castleman disease: Correlation with activity, severity, inflammatory and virologic parameters. J Infect Dis. 2015;212(8):1250–60.PubMedPubMedCentral

36.

Sathekge M, Maes A, Van de Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43(5):349–66.PubMed

37.

Sathekge M, Goethals I, Maes A, van de Wiele C. Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging. 2009;36(7):1176–84.PubMed

38.

Liu Y. Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med. 2011;25(8):536–46.PubMed

39.

Kim IJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S, et al. Double-phase ¹⁸F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging. 2008;35(4):808–14.PubMed

40.

Sathekge M, Maes A, D'Asseler Y, Vorster M, Gongxeka H, Van de Wiele C. Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging. 2012;39(7):1184–90.PubMed

41.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, et al. Persisting PET-CT lesion activity and Mycobacterium tuberculosis mRNA after pulmonary tuberculosis cure. Nat Med. 2016;22(10):1094–100.PubMedPubMedCentral

42.

Lawal I, Fourie B, Mathebula M, Moagi I, Lengana T, Moeketsi N, et al. FDG-PET/CT as a non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.233783.CrossRefPubMed

43.

Ohira H, Ardle BM, deKemp RA, Nery P, Juneau D, Renaud JM, et al. Inter- and intraobserver agreement of ¹⁸F-FDG PET/CT image interpretation in patients referred for assessment of cardiac sarcoidosis. J Nucl Med. 2017;58(8):1324–9.PubMed

44.

Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of ¹⁸F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nucl Med. 2016;41(7):327–39.

45.

Lu Y, Grant C, Xie K, Sweiss NJ. Suppression of myocardial ¹⁸F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. Clin Nucl Med. 2017;42(2):88–94.PubMed

46.

Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol. 2017;24(2):413–24.PubMed

47.

Duftner C, Dejaco C, Sepriano A, Falzon L, Schmidt WA, Ramiro S. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open. 2018;4(1):e000612.PubMedPubMedCentral

48.

Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, et al. The impact of ¹⁸F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging. 2012;39(2):344–53.PubMed

49.

Hooisma GA, Balink H, Houtman PM, Slart RH, Lensen KD. Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study. Clin Rheumatol. 2012;31(5):873–5.

50.

Zhang Y, Shen M. Value of positron emission tomography/computed tomography in the diagnosis and disease activity assessment of systemic vasculitis. Chin J Allergy Clin Immunol. 2014;8(1):70–5 [Article in Chinese].

51.

Nielsen BD, Gormsen LC, Hansen IT, Keller KK, Therkildsen P, Hauge EM. Three days of high-dose glucocorticoid treatment attenuates large-vessel ¹⁸F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018;45(7):1119–28.PubMed

52.

Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. ¹⁸F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439–49.PubMedPubMedCentral

53.

Bleeker-Rovers CP, Bredie SJ, van der Meer JW, Corstens FH, Oyen WJ. F-18-fluorodeoxyglucose positron emission tomography in diagnosis and follow-up of patients with different types of vasculitis. Neth J Med. 2003;61(10):323–9.PubMed

54.

Kemna MJ, Vandergheynst F, Vöö S, Blocklet D, Nguyen T, Timmermans SA, et al. Positron emission tomography scanning in anti-neutrophil cytoplasmic antibodies-associated vasculitis. Medicine (Baltimore). 2015;94(20):e747.

55.

Frary EC, Hess S, Gerke O, Laustrup H. 18F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography can reliably rule-out infection and cancer in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis suspected of disease relapse. Medicine (Baltimore). 2017;96(30):e7613.

56.

Trad S, Bensimhon L, El Hajjam M, Chinet T, Wechsler B, Saadoun D. 18F-fluorodeoxyglucose-positron emission tomography scanning is a useful tool for therapy evaluation of arterial aneurysm in Behçet's disease. Joint Bone Spine. 2013;80(4):420–3.PubMed

57.

Dong MJ, Wang CQ, Zhao K, Wang GL, Sun ML, Liu ZF, et al. 18F-FDG PET/CT in patients with adult-onset Still's disease. Clin Rheumatol. 2015;34(12):2047–56.PubMed

58.

Jiang L, Xiu Y, Gu T, Dong C, Wu B, Shi H. Imaging characteristics of adult onset Still's disease demonstrated with ¹⁸F-FDG PET/CT. Mol Med Rep. 2017;16(3):3680–6.PubMed

59.

Yamashita H, Kubota K, Takahashi Y, Minamimoto R, Morooka M, Kaneko H, et al. Clinical value of (18)F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature. Mod Rheumatol. 2014;24(4):645–50.PubMed

60.

Li Y, Zhou Y, Wang Q. Multiple values of ¹⁸F-FDG PET/CT in idiopathic inflammatory myopathy. Clin Rheumatol. 2017;36(10):2297–305.PubMed

61.

Martis N, Viau P, Zenone T, Andry F, Grados A, Ebbo M, et al. Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis. Eur Radiol. 2019;29(12):6708–16.PubMed

62.

Mahmmod S, Martínez R, de Llano S. 18F-FDG PET detection of unknown primary malignancy in dermatomyositis. Clin Nucl Med. 2012;37(8):e204–205.

63.

Kundrick A, Kirby J, Ba D, Leslie D, Olsen N, Foulke G. Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin Arthritis Rheum. 2019;49(1):140–4.PubMed

64.

Yamashita H, Kubota K, Takahashi Y, Minaminoto R, Morooka M, Ito K, et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol. 2012;22(5):705–11.PubMed

65.

Rehak Z, Sprlakova-Pukova A, Kazda T, Fojtik Z, Vargova L, Nemec P. 18F-FDG PET/CT in polymyalgia rheumatica-a pictorial review. Br J Radiol. 2017;90(1076):20170198.PubMedPubMedCentral

66.

Kubota K, Yamashita H, Mimori A. Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. Semin Nucl Med. 2017;47(4):408–24.PubMed

67.

Lei W, Zeng H, Zeng DX, Zhang B, Zhu YH, Jiang JH, et al. (18)F-FDG PET-CT: a powerful tool for the diagnosis and treatment of relapsing polychondritis. Br J Radiol. 2016;89(1057):20150695.PubMed

68.

Qiu LH, Wang Q. The value of 18F-flurodeoxyglucose positron emission tomography/computed tomography for detecting the relapsing polychondritis in patients with fever of unknown origin. Chin J Rheumatol. 2017;21(12):841–3 [Article in Chinese].

69.

Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with ¹⁸F-FDG PET. J Nucl Med. 2004;45(6):956–64.PubMed

70.

Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med. 2009;23:783–91.PubMed

71.

Kubota K, Ito K, Morooka M, Minamimoto R, Miyata Y, Yamashita H, et al. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci. 2011;1228:29–38.PubMed

72.

Zhang J, Chen H, Ma Y, Xiao Y, Niu N, Lin W, et al. Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective chort study. Eur J Nucl Med Mol Imaging. 2014;41(8):1624–34.PubMedPubMedCentral

73.

Zhao Z, Wang Y, Guan Z, Jin J, Huang F, Zhu J. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases. Clin Exp Rheumatol. 2016;34(1):119–25.PubMed

74.

Berti A, Della-Torre E, Gallivanone F, Canevari C, Milani R, Lanzillotta M, et al. Quantitative measurement of ¹⁸F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology. 2017;56(12):2084–92.PubMed

75.

Mavrogeni S, Markousis-Mavrogenis G, Kolovou G. IgG4-related cardiovascular disease. The emerging role of cardiovascular imaging. Eur J Radiol. 2017;86:169–75.PubMed

76.

Curiel R, Akin EA, Beaulieu G, DePalma L, Hashefi M. PET/CT imaging in systemic lupus erythematosus. Ann NY Acad Sci. 2011;1228:71–80.PubMed

77.

Makis W, Ciarallo A, Gonzalez-Verdecia M, Probst S. Systemic lupus erythematosus associated pitfalls on ¹⁸F-FDG PET/CT: reactive follicular hyperplasia, Kikuchi-Fujimoto disease, inflammation and lymphoid hyperplasia of the spleen mimicking lymphoma. Nucl Med Mol Imaging. 2018;52(1):74–9.PubMed

78.

Boellaard R, Delgado-Bolton R, Oyen W, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.PubMed

Titel: Expert Consensus on clinical application of FDG PET/CT in infection and inflammation
verfasst von: Yaming Li
Qian Wang
Xuemei Wang
Xuena Li
Hua Wu
Quanshi Wang
Zhiming Yao
Weibing Miao
Xiaohua Zhu
Fengchun Hua
Xiaoli Zhang
Chao Cheng
Weifang Zhang
Qingyi Hou
Yuan Li
Xiao-Feng Li
Publikationsdatum: 21.02.2020
Verlag: Springer Singapore
Erschienen in: Annals of Nuclear Medicine / Ausgabe 5/2020
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-020-01449-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Ten-year prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population

Feasibility of gamma camera-based GFR measurement using renal depth evaluated by lateral scan of 99mTc-DTPA renography

Relationships between amyloid levels, glucose metabolism, morphologic changes in the brain and clinical status of patients with Alzheimer’s disease

Toyama H, Li Y, Hatazawa J, Huang G, Kubota K (eds): PET/CT for inflammatory diseases: basic sciences, typical cases, and review

Pet tracers for vulnerable plaque imaging

18F-FDG PET/CT in lung adenosquamous carcinoma and its correlation with clinicopathological features and prognosis